Circumstances under which practice does not make perfect: A review of the practice effect literature in schizophrenia and its relevance to clinical treatment studies

Neuropsychopharmacology

Volumn 35, Issue 5, 2010, Pages 1053-1062

  Goldberg, Terry E ^a   Keefe, Richard S E ^b   Goldman, Robert S ^c   Robinson, Delbert G ^a   Harvey, Philip D ^d  

^a ZUCKER HILLSIDE HOSPITAL   (United States)

^b DUKE UNIVERSITY   (United States)

^c PFIZER INC   (United States)

^d EMORY UNIVERSITY   (United States)

Author keywords

Clinical pharmacology trials; Cognition; Learning and memory; Practice effects; Schizophrenia antipsychotics

Indexed keywords

DONEPEZIL; HALOPERIDOL; NEUROLEPTIC AGENT; NOOTROPIC AGENT; OLANZAPINE; PLACEBO; RISPERIDONE;

ATTENTION; BRAIN AQUEDUCT; CINGULATE GYRUS; CLINICAL TRIAL; COGNITION; COGNITIVE DEFECT; DAILY LIFE ACTIVITY; DELUSION; DISABILITY; DISEASE DURATION; DRUG APPROVAL; DRUG EXPOSURE; EPISODIC MEMORY; HALLUCINATION; HUMAN; INSULA; INTELLIGENCE QUOTIENT; LEARNING; METHODOLOGY; MOTOR PERFORMANCE; NEUROBIOLOGY; NEUROPSYCHOLOGICAL TEST; PLACEBO EFFECT; PREDICTION; PREFRONTAL CORTEX; PRIORITY JOURNAL; PSYCHOMETRY; RELIABILITY; REVIEW; SCHIZOPHRENIA; SOCIAL DISABILITY; STATISTICAL ANALYSIS; STIMULUS; TREATMENT OUTCOME; WORKING MEMORY;

ANTIPSYCHOTIC AGENTS; COGNITION DISORDERS; HUMANS; NEUROPSYCHOLOGICAL TESTS; PRACTICE (PSYCHOLOGY); SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 77949540094     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/npp.2009.211     Document Type: Review

References (50)

1. Ahn YM, Lee KY, Kim CE, Kim JJ, Kang DY, Jun TY et al (2009). Changes in neurocognitive function in patients with schizophrenia after starting or switching to amisulpride in comparison with the normal controls. J Clin Psychopharmacol 29: 117-123.
2. Albus M, Hubmann W, Mohr F, Hecht S, Hinterberger-Weber P, Seitz NN et al (2006). Neurocognitive functioning in patients with first-episode schizophrenia. Eur Arch Psychiatry Clin Neurol 256: 442-451.
3. Basso MR, Bornstein RA, Lang JM (1999). Practice effects on commonly used measures of executive function across twelve months. Clin Neuropsychol 13: 283-292.
4. Beglinger LJ, Gaydos B, Tangphao-Daniels O, Duff K, Kareken DA, Crawford J et al (2005). Practice effects and the use of alternate forms in serial neuropsychological testing. Arch Clin Neuropsy-chol 20: 517-529.
5. Boulay LJ, Labelle A, Bourget D, Robertson S, Habib R, Tessier P et al (2007). Dissociating medication effects from learning and practice effects in a neurocognitive study of schizophrenia: olanzapine versus haloperidol. Cogn Neuropsychiatry 12: 322-338.
6. Bowie CR, Reichenberg A, Patterson TL, Heaton RK, Harvey PD (2006). Determinants of real world functional performance in schizophrenia subjects: correlations with cognition, functional capacity, and symptoms. Am J Psychiatry 163: 418-425.
7. Crespo-Facorro B, Rodŕiguez-Sánchez JM, Pérez-Iglesias R, Mata I, Ayesa R, Ramirez-Bonilla M et al (2009). Neurocognitive effectiveness of haloperidol, risperidone, and olanzapine in first-episode psychosis: a randomized, controlled 1-year follow-up comparison. J Clin Psychiatry 70: 717-729.
8. Davidson M, Galderisi S, Weiser M, Werbeloff N, Fleischhacker WW, Keefe RS et al (2009). Cognitive effects of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: a randomized, open-label clinical trial (EUFEST). Am J Psychiatry 166(6): 675-682.
9. de la Fuente-Fernández R, Schulzer M, Stoessl AJ (2002). The placebo effect in neurological disorders. Lancet Neurol 1: 85-91.
10. Durstewitz D, Seamans JK, Sejnowski TJ (2000). Dopamine-mediated stabilization of delay-period activity in a network model of prefrontal cortex. J Neurophysiol 83: 1733-1750.
11. Falleti MG, Maruff P, Collie A, Darby DG (2006). Practice effects associated with the repeated assessment of cognitive function using the CogState battery at 10-minute, one week and one month test-retest intervals. J Clin Exp Neuropsychol 28: 1095-1112.
12. Gold JM, Rehkemper G, Binks SW, Carpenter CJ, Fleming K, Goldberg TE et al (2000). Learning and forgetting in schizophrenia. J Abnorm Psychol 109: 534-538.
13. Goldberg TE, Goldman RS, Burdick KE, Malhotra AM, Lencz T, Patel RC et al (2007). Cognitive improvements after treatment with second-generation antipsychotic medications in first episode schizophrenia: is it a practice effect? Arch Gen Psychiatry 64: 1115-1122.
14. Goldberg TE, Green MF (2002). Neurocognitive functioning in patients with schizophrenia: an overview. In: Davis KL, Charney D, Coyle JT, Nemeroff C (eds). Neuropsychopharmacology: The Fifth Generation of Progress. Raven Press: New York. pp 657-670.
15. Goldberg TE, Koppel J, Kechlisen L, Christen E, Werringloer U, Conejero-Goldberg C et al. Performance-based measures of everyday function in mild cognitive impairment. Am J Psychiatry (in press).
16. Green MF (1996). What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry 153: 321-330.
17. Harvey PD, Howanitz E, Parrella M, White L, Davidson M, Mohs RC et al (1998). Symptoms, cognitive functioning, and adaptive skills in geriatric patients with lifelong schizophrenia: a comparison across treatment sites. Am J Psychiatry 155: 1080-1086.
18. Harvey PD, Keefe RS (2001). Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment. Am J Psychiatry 158(2): 176-184.
19. Harvey PD, Koren D, Reichenberg A, Bowie CR (2006). Negative symptoms and cognitive deficits: what is the nature of their relationship? Schizophr Bull 32: 250-258.
20. Harvey PD, Moriarty PJ, Serper MR, Schnur E, Lieber D (2000). Practice-related improvement in information processing with novel antipsychotic treatment. Schizophr Res 46: 139-148.
21. Harvey PD, Palmer BW, Heaton RK, Mohamed S, Kennedy J, Brickman A (2005). Stability of cognitive performance in older patients with schizophrenia: an 8-week test-retest study. Am J Psychiatry 162: 110-117.
22. Heaton RK, Gladsjo JA, Palmer BW, Kuck J, Marcotte TD, Jeste DV (2001). Stability and course of neuropsychological deficits in schizophrenia. Arch Gen Psychiatry 58: 24-32.
23. Heaton RK, Paulsen JS, McAdams LA, Kuck J, Zisook S, Braff D et al (1994). Neuropsychological deficits in schizophrenics. Relationship to age, chronicity, and dementia. Arch Gen Psychiatry 51: 469-476.
24. Heaton RK, Temkin N, Dikmen S, Avitable N, Taylor MJ, Marcotte TD et al (2001). Detecting change: a comparison of three neuropsychological methods, using normal and clinical samples. Arch Clin Neuropsychol 16: 75-91.
25. Hill SK, Shuepbach D, Herbener ES, Keshavan MS, Sweeney JA (2004). Pretreatment and longitudinal studies of neuro-psychological deficits in antipsychotic-näive patients with schizophrenia. Schizophr Res 68: 49-63.
26. Hoff AL, Sakuma M, Wieneke M, Horon R, Kushner M, DeLisi LE (1999). Longitudinal neuropsychological follow-up study of patients with first-episode schizophrenia. Am J Psychiatry 156: 1336-1341.
27. Keefe RS, Bilder RM, Davis SM, Harvey PD, Palmer BW, Gold JM et al (2007). Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Arch Gen Psychiatry 64: 633-647.
28. Keefe RS, Malhotra AK, Meltzer H, Kane JM, Buchanan RW, Murthy A et al (2008). Efficacy and safety of donepezil in patients with schizophrenia or schizoaffective disorder: significant placebo/practice effects in a 12-week, randomized, double-blind, placebo-controlled trial. Neuropsychopharmacology 33: 1217-1228.
29. Keefe RS, Perkins DO, Gu H, Zipursky RB, Christensen BK, Lieberman JA (2006). A longitudinal study of neurocognitive function in individuals at-risk for psychosis. Schizophr Res 88: 26-35.
30. Keefe RS, Silva SG, Perkins DO, Lieberman JA (1999). The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis. Schizophr Bull 5: 201-222.
31. Keetch KM, Schmidt RA, Lee TD, Young DE (2005). Especial skills: their emergence with massive amounts of practice. J Exp Psychol Hum Percept Perform 31: 970-978.
32. Kelly AM, Garavan H (2005). Human functional neuroimaging of brain changes associated with practice. Cereb Cortex 15: 1089-1102.
33. Logan GD (2002). An instance theory of attention and memory. Psychol Rev 109: 376-400.
34. McCaffrey RJ, Duff K, Westervelt HJ (2000). Practioner's Guide to Evaluating Change with Neuropsychological Testing Instruments. Kluwer Academic: New York.
35. Mishara A, Goldberg TE (2004). A meta-analysis of the effects of typical neuroleptic medications on cognition: reopening the book. Biol Psych 55: 1013-1022.
36. Miyake A, Shah P (1999). Models of Working Memory: Mechanisms of Active Maintenance and Executive Control. Cambridge University Press: New York.
37. Mohamed S, Rosenheck R, Swartz M, Stroup S, Lieberman JA, Keefe RS (2008). Relationship of cognition and psychopathology to functional impairment in schizophrenia. Am J Psychiatry 165: 940-943.
38. Mozley LH, Verma A, Vogt R, Gargano C, Potter W, Egan MF (2008). Comparison of cognition batteries for use in clinical trials of schizophrenia. ACNP Annual Meeting. Scottsdale, AZ, USA.
39. Nuechterlein KH, Green MH (2006). MATRICS Consensus Cognitive Battery. MATRICS Assessment: Los Angeles.
40. Nuechterlein KH, Green MF, Kern RS, Baade LE, Barch DM, Cohen JD et al (2008). The MATRICS consensus cognitive battery, Part 1: test selection, reliability, and validity. Am J Psychiatry 165: 203-213.
41. Raichle ME, Fiez JA, Videen TO, MacLeod AM, Pardo JV, Fox PT et al (1994). Practice related changes in human brain functional anatomy during nonmotor learning. Cereb Cortex 4: 8-26.
42. Salthouse TA, Schroeder DH, Ferrer E (2004). Estimating retest effects in longitudinal assessments of cognitive functioning in adults between 18 and 60 years of age. Dev Psychol 40: 813-822.
43. Szöke A, Trandafir A, Dupont ME, Méary A, Schürhoff F, Leboyer M (2008). Longitudinal studies of cognition in schizophrenia: meta-analysis. Br J Psychiatry 192: 248-257.
44. Uchiyama CL, D'Elia LF, Dellinger AM, Becker JT, Selnes OA, Wesch JE et al (1995). Alternate forms of the auditory-verbal learning test: issues of test comparability, longitudinal reliability, and moderating variables. Arch Clin Neuropsychol 10: 133-145.
45. Velligan DI, Mahurin RK, Diamond PL, Hazleton BC, Eckert SL, Miller AL (1997). The functional significance of symptomatology and cognitive function in schizophrenia. Schizophr Res 25: 21-31.
46. Weickert TW, Goldberg TE (2005). First-and second-generation antipsychotic medication and cognitive processing in schizophrenia. Curr Psychiatry Rep 7: 304-310.
47. Weickert TW, Goldberg TE, Marenco S, Bigelow LB, Egan MF, Weinberger DR (2003). Comparison of cognitive performances in a placebo period and an atypical neuroleptic treatment period in schizophrenia. Neuropsychopharmacology 28: 1491-1500.
48. Weickert TW, Terrazas A, Bigelow LB, Malley JD, Hyde T, Egan MF et al (2002). Habit and skill learning in schizophrenia: evidence of normal striatal processing with abnormal cortical input. Learn Mem 9: 430-442.
49. Woodward ND, Purdon SE, Meltzer HY, Zald DH (2005). A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia. Int J Neuropsy-chopharm 8: 457-472.
50. Woodward ND, Purdon SE, Meltzer HY, Zald DH (2007). A meta-analysis of cognitive change with haloperidol in clinical trials of atypical antipsychotics: dose effects and comparison to practice effects. Schizophr Res 89: 211-224.